Medpace Holdings (MEX:MEDP) PE Ratio without NRI: 22.97 (As of Jul. 25, 2026) — 24% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:MEDP Medpace Holdings Inc MEX:MEDP
95 GF Score
Price MXN7,022.03
GF Value MXN6,131.53
! 2 Warning Signs
View Full Analysis

What is Medpace Holdings PE Ratio without NRI?

Medpace Holdings MEX:MEDP 95 PE Ratio without NRI is 22.97 as of Jul. 25, 2026, which is 24% below its 10-year median of 30.04. GuruFocus rates MEX:MEDP with a GF Score™ of 95/100 and a GF Value™ of MXN6,131.53. The stock has 2 warning signs investors should review. Among 96 Medical Diagnostics & Research companies, Medpace Holdings ranks worse than 60.42% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-25), Medpace Holdings's share price is MXN7022.03. Medpace Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was MXN306.23. Therefore, Medpace Holdings's PE Ratio without NRI for today is 22.97.

During the past 13 years, Medpace Holdings's highest PE Ratio without NRI was 297.30. The lowest was 20.92. And the median was 30.04.

Medpace Holdings's EPS without NRI for the three months ended in Jun. 2026 was MXN74.16. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was MXN306.23.

As of today (2026-07-25), Medpace Holdings's share price is MXN7022.03. Medpace Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was MXN306.23. Therefore, Medpace Holdings's PE Ratio (TTM) for today is 22.97.

During the past years, Medpace Holdings's highest PE Ratio (TTM) was 297.30. The lowest was 21.92. And the median was 34.09.

Medpace Holdings's EPS (Diluted) for the three months ended in Jun. 2026 was MXN74.16. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was MXN306.23.

Medpace Holdings's EPS (Basic) for the three months ended in Jun. 2026 was MXN75.21. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was MXN312.17.


Medpace Holdings  (MEX:MEDP) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Medpace Holdings PE Ratio without NRI Related Terms


Medpace Holdings PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Medpace Holdings's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medpace Holdings PE Ratio without NRI Chart

Medpace Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.88 29.58 34.32 26.28 36.24

Medpace Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.34 35.96 36.24 30.18 31.04

MEX:MEDP vs ICLR, RVTY, CRL: PE Ratio without NRI Comparison

For the Diagnostics & Research subindustry, Medpace Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medpace Holdings PE Ratio without NRI vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's PE Ratio without NRI falls into.


MEX:MEDP
95GF Score
Medpace Holdings Inc MEX:MEDP
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medpace Holdings PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Medpace Holdings's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=7022.03/305.638
=22.97

Medpace Holdings's Share Price of today is MXN7022.03.
Medpace Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN306.23.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 22.97 mean?
Medpace Holdings (MEX:MEDP) has a PE Ratio without NRI of 22.97 as of Jul. 25, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Medpace Holdings and its competitors. This is 24% below median its historical median of 30.04. Over the past decade, Medpace Holdings' PE Ratio without NRI has ranged from 20.92 to 297.30. According to the industry distribution chart, Medpace Holdings ranks #58 out of 96 companies in the Medical Diagnostics & Research industry, placing it in the top 60.4%.
Is Medpace Holdings' PE Ratio without NRI too high?
Medpace Holdings' current PE Ratio without NRI of 22.97 is 24% below median its 10-year median of 30.04. Over the past 10 years, this metric has ranged from a low of 20.92 to a high of 297.30. The Medical Diagnostics & Research industry median PE Ratio without NRI is 29.50. Medpace Holdings' value of 22.97 is 22.1% below this industry median. Based on the distribution chart, Medpace Holdings ranks #58 out of 96 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Medpace Holdings has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' PE Ratio without NRI compare to ICLR and RVTY?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #58 out of 96 companies for PE Ratio without NRI. This places Medpace Holdings in the lower half of its industry. The industry median PE Ratio without NRI is 29.50. Medpace Holdings' value of 22.97 is 22.1% below this benchmark. Historically, Medpace Holdings' own PE Ratio without NRI has ranged from 20.92 to 297.30 over the past decade. While the company's 10-year median is 30.04 vs. the industry median of 29.50, Medpace Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Diagnostics & Research company?
The median PE Ratio without NRI among Medical Diagnostics & Research companies is 29.50, based on 96 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medpace Holdings's current PE Ratio without NRI of 22.97 is 22.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Medpace Holdings and its competitors. For the Medical Diagnostics & Research industry, the median PE Ratio without NRI is 29.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current PE Ratio without NRI is 22.97, which is 24% below median its own 10-year median of 30.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Medpace Holdings (MEX:MEDP) has a current PE Ratio without NRI of 22.97. The stock's GF Value™ is MXN6,131.53, compared to a current price of MXN7,022.03 — trading 14.5% above its estimated fair value. The current PE Ratio without NRI is 22.97, which is 24% below median its 10-year median of 30.04 and 22.1% below the Medical Diagnostics & Research industry median of 29.50. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Medpace Holdings (MEX:MEDP), the current PE Ratio without NRI is 22.97 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medpace Holdings (MEX:MEDP) Overvalued in 2026?

Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued. The current stock price of MXN7,022.03 is trading 14.5% above its estimated GF Value™ of MXN6,131.53.

Key valuation signals for MEX:MEDP:

  • PE Ratio without NRI: 22.97 (24% below median its 10-year median of 30.04)
  • GF Value™: MXN6,131.53 vs. price of MXN7,022.03 (14.5% above fair value)
  • GF Score™: 95/100 with 2 warning signs
  • Industry Position: 22.1% below the Medical Diagnostics & Research median (#58 of 96)

No single metric tells the full story. See the MEX:MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medpace Holdings Business Description

Other Exchanges MEDP:USA01P:Germany
Address 5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score

Get the complete analysis for MEX:MEDP

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN7,022.03
Price
MXN6,131.53
GF Value